Semax vs DSIP
Both Semax and DSIP are used for neuroprotection. Here's how their evidence, dosing, and regulatory status actually compare.
Semax
Evidence BSemax (MEHFPGP)
A synthetic ACTH fragment that increases BDNF levels and enhances focus, memory, and mental clarity. Delivered intranasally for rapid cognitive effects.
View full Semax profile →DSIP
Evidence CDelta Sleep-Inducing Peptide
A nonapeptide originally isolated from rabbit blood after EEG-defined slow-wave sleep induction. Inconsistent human evidence for sleep but explored for stress and analgesia.
View full DSIP profile →Side-by-Side
| Attribute | Semax | DSIP |
|---|---|---|
| Evidence Grade | B | C |
| FDA Status | Not FDA-approved in US — approved in Russia for stroke and cognitive disorders | Not FDA-approved — research compound |
| Typical Dose | 200–600 mcg intranasal, morning | 100–300 mcg before bed (subcutaneous) |
| Clinics Indexed | 89 | 38 |
| Categories | cognitive, neuroprotection | sleep, neuroprotection |
Key reported benefits — Semax
- ✓BDNF increase
- ✓Enhanced focus
- ✓Memory improvement
- ✓Neuroprotection
Key reported benefits — DSIP
- ✓Slow-wave-sleep signals (preclinical)
- ✓Stress/cortisol modulation
- ✓Possible analgesic effect
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.